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A B S T R A C T
Hipothalamo-pituitary-adrenal (HPA) axis is a very complicated control system
playing an important role in stress reaction, where glucocorticoids suppress the auto-
nomic (vegetative), endocrine, immunologic and psychic responses to stressful stimuli.
We described the marked clinical, physiological, and biochemical connection between os-
teoporosis and major depressive disorder (MDD). Both conditions are associated with a
hyperactive HPA axis and LC/NE system, and hence with increased CRH, cortisol, and
catecholamine secretion. There are numerous states or diseases associated with osteopo-
rosis and we were looking for a hypercorticism value as a one of these. Some recent stud-
ies demonstrated that earlier history of MDD was associated with marked osteoporosis.
In MDD there are two well-documented biochemical abnormalities: hypercortisolism
and its resistance to dexamethasone suppression. The present study included 31 MDD
patients (19 males and 12 females, mean age 37  1.3, age range 29–41 years), and 17
healthy male volunteers (mean age 39  1.6, age range 34–45 years). In each of our pa-
tients 24-hour urinary free cortisol, serum cortisol level at 8 a.m. and 5 p.m., cortisol in
dexamethasone suppression test and bone mineral density were measured. We have,
therefore, analyzed a group of young men and women with normal menstrual cycles,
who were without signs of osteoporosis in the beginning, and who received anti-depres-
sive therapy for many years. Analysis showed that increased levels of cortisol and the oc-
currence of osteoporosis, that developed as the result of elevated cortisol level. For our
workshop we used nonparametric rang-correlation with Spearman’s ro = –0.805, with
statistic significant at the 0.01 level (2-tailed). Patients under long-term history of de-
pression could develop a very stronger type of osteoporosis i.e. it is before known that the
patients with untreated Cushing syndrome developed hard osteoporosis.
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Introduction
Osteoporosis is a skeletal disorder
characterized by two elements that dis-
tinguish it from other causes of osteo-
penia such as hyperparathyroidism and
osteomalacia1; low bone mass and micro-
architectural disruption2. Osteoporosis is
the most common bone disease and its
leading to fracture is a common prob-
lem3,4. In men, as in women, the inci-
dence of hip fractures increases exponen-
tially with aging although the increase
begins approximately 5 to 10 years la-
ter5,6. Approximately one-half of these
fractures are vertebral fractures, one-
quarter are hip fractures, and one-quar-
ter are Colles’ fractures7,8. Osteoporosis is
a leading cause of morbidity and mortal-
ity in elderly people.
The disorders that cause osteoporosis
are similar in men and women9–11: estro-
gen deficiency – primarily in postmeno-
pausal women12,13, hyperparathyroidism,
hyperthyroidism, hypogonadism in men14,
glucocorticoid therapy15, genetic fac-
tors16,17, cigarette smoking and alcohol
intake, lower calcium intake, decreases
in physical activity and muscle strenght18,
gastrointestinal disease8, vitamin D defi-
ciency, anti-convulsant therapy and
stress factors with depression19–22.
The usual clinical manifestations of
osteoporosis are low-trauma fractures
and radiographic osteopenia detected by
chance or during evaluation for musculo-
sceletal pain, usually back pain9.
Measurements of bone mineral den-
sity are usually recommended, and if bo-
ne mineral density is lower than experi-
enced for age and no cause is apparent,
further studies are indicated; measure-
ments of serum testosterone, thyrotropin,
calcium, alkaline phosphatase, 25-hydro-
xyvitamin D, parathyroid hormone, uri-
nary calcium and creatinine, a complete
blood count, serum and urine protein
electrophoresis, iliac crest bone biop-
sy10–12.
If a cause of osteoporosis can be identi-
fied, potential offending agents should be
eliminated whenever possible. As a gen-
eral rule, patient should receive adequate
calcium (1000 mg/day) and vitamin D
(800 IU/day) supplementation. A weight-
bearing exercise regimen also may be be-
neficial by given association of reduced
physical activity.
Mayor depressive disorder (MDD) is a
syndrome of persistently sad, dysphoric
mood accompanied by sleep and appetite
disturbances, and inability to experience
pleasure18. The diagnosis of MDD is ma-
de when the patient meets the DSM-IV
criteria. At least five of the following
symptoms must be present during a 2-
week period and show change from the
previous condition: depressed mood most
of the day, nearly every day; anhedonia
and diminished interest in general; sig-
nificant weight change not related to diet;
sleep disturbances; psychomotor agita-
tion or retardation, loss of energy; feeling
of worthlessness or inappropriate guilt;
concentration disturbances; recurrent
thoughts of death; suicidal ideas or spe-
cific plan for committing suicide.
In MDD, there are two well-documen-
ted biochemical abnormalities;: hyper-
cortisolism and its resistance to dexa-
methasone suppression. Activation of the
pituitary-adrenal axis is fairly specific of
depression among other conditions of pri-
mary affective disorders and may be ob-
served in as many 40–60% of patients in
some series18,19.
These findings have eventually led to
the routine use of dexamethasone sup-
pression test (DST) as a biologic tool for
both the diagnosis and follow-up of such
patients.
Psychotherapy, associated with anti-
depressants(serotonin re-uptake inhibi-
tors, tricyclic antidepressants, anxiolyt-
ics and mood stabilizers) have been found
to improve impulsive behavior.
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Subjects and Methods
The study included 31 patients with
MDD, 19 males and 12 females, mean age
37  1.3, age range 29–41 years, and 17
healthy male volunteers (mean age 39 
1.6, age range 34–45 years). In order to
determine the hypercortisolic state, it
was essential to develop a tool to assess
the cortisolic state and to identify, for a
given individual, whether it was inappro-
priately high. An ideal parameter would
be the one that shows no overlapping be-
tween normal subjects, including the
obese and patients with hypercortisolic
state of whatever etiology.
Plasma cortisol is measured by two
competitive protein binding assay or re-
cently by more specific immunoassays.
Plasma free cortisol is the best indicator
of the cortisolic state. It is a biologically
relevant and highly sensitive parameter.
Serum cortisol level was determined
by standard radioimmunoassay (RIA) us-
ing 125J labeled hormone, since it binds
non-labeled serum cortisol to specific an-
tibodies according to their concentration
in the radioactive mixture. Venous blood
samples of 5 ml were obtained in the
morning (8 a.m.) and afternoon (5 p.m.)
after 30-min bed rest. According to cyclic
hypothalamic secretion of CRF, the rate
of cortisol secretion in a healthy person is
higher in the early morning, and lower in
the early evening. Falsely elevated val-
ues can be found in pregnancy and in
women taking oral contraceptives, whe-
reas no normal diurnal variations are
found in stress patients. According to our
laboratory normal values are 138–800
nmol/l at 8 a.m. and 50–70% of the morn-
ing values at 5 p.m.
Free 24-h urinary cortisol excretion is
an almost ideal marker of the cortisolic
state. Urinary cortisol is measured by the
competitive protein-binding assay after
extraction or by immunoassay. Patients
were instructed to collect urine samples
after first morning void until the next
morning, including first void on the next
day. Normal values are 150–750 mmol/
24h. Since it correlates with the levels of
plasma free cortisol, urinary cortisol ex-
cretion has several invaluable qualities:
it is biologically relevant, being a reflec-
tion of how much biologically active, free
cortisol has been circulating over the last
24-h period; it is highly sensitive marker.
It is not altered in obese patients in estro-
gen-treated females or by drugs or condi-
tions that modify cortisol metabolism.
Dexamethasone suppression test in-
cluded oral administration of two 0.5-mg
dexamethasone tablets at 11 p.m, follow-
ed by venous blood sampling at 8 a.m.
and 5 p.m. on the next day. In DST, syn-
thetic steroid analogs have been chosen
for their high glucocorticoid potency; they
would suppress ACTH when given in mi-
nute amounts as compared to the daily
amount or normally secreted cortisol. It
has been established that 0.5 mg of dexa-
methasone given every 6 hours in eight
doses (2 mg/day) induce almost complete
suppression.
In each of our patients, serum cortisol
level, 24h urinary free cortisol and DST
were determined.
Results
Results of the study showed the mean
basal 24-h urinary cortisol in MDD pa-
tients to be 1067  61.8 nmol/l Serum cor-
tisol at 8 p.m. was 618  43.2 nmol/l, and
at 5 p.m. 347  34.2 nmol/l. Cortisol in
DST was 165  36.8 nmol/l.
Plasma cortisol levels in MDD pa-
tients were just above the normal range.
Also, in patient with MDD we found defi-
cient cortisol suppression in DST test.
These results indicated that, although
MDD patients showed an increased the
urine cortisol level. They had some circa-
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dian rhythm of cortisol preserved (Fig-
ures 1 and 2).
In our examination, we found signifi-
cant correlation between years of therapy
and degree of osteoporosis in patient with
MDD. (Figure 4) As we see, the patient
who was longer time on antidepressant
therapy, had more chance to develop os-
teoporosis. As we could see, the patient
with MDD had statistical significant
higher levels of cortisol in 24-h urine.
In our workshop we used (was recom-
mended) the nonparametric rang-correla-
tion, in which the Spearman’s ro =
–0.805, and correlation is significant at
the 0.01 level (p < 0.01) (Tables 2 and 3).
Discussion
The hypothalamo-pituitary-adrenal
(HPA) axis is a very complex control sys-
tem playing an important role primarily
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TABLE 1




A B C Cort/24 Cort /dex
MDD 31 19 12 37  1.3 12 6 31 1067 + 61 165 + 36
Controls 17 17 0 39  1.6 0 0 0 590 + 87 86 + 37














Fig. 1. Urinary free cortisol in patients with











Fig. 2. Plasma cortisol in patients with mayor
depressive disorder (MDD) and healthy volun-
teers at 8 a.m. and 4 p.m.
Fig. 3. Urinary free cortisol, plasma cortisol at
8 a.m. and 5 p.m., and cortisol in dexametha-
sone suppression test in patients with major de-
pressive disorder (MDD) and in healthy control
volunteers.
in stress reaction23. Glucocorticoids are
secreted in response to stressful condi-
tions, and have an important task to
block the functions of stress mediators
that have previously been brought to lib-
eration. In other words, glucocorticoids
suppress the autonomic (vegetative), be-
havioral, endocrine and immunologic re-
sponses to stressful stimuli in a time-de-
pendent way.
HPA axis is under control of various
neurotransmitter systems. Some authors
consider that serotonin, acetylcholine
and histamine show stimulatory, and no-
radrenaline and GABA inhibitory effects.
During stress, HPA axis acts differently
according to the actual task, i.e. »to fight
or to flight«. Immobilization reflex (with-
drawal reaction from fight) with motility
inhibition and conservation of energy is
under control of hyppocampus and adre-
nal cortex activation by ACTH and cor-
ticosterone increase24–26.
Biological abnormality is frequently
observed in patients with major depres-
sion, presumably secondary to ACTH hy-
persecretion. The ability of the glucocor-
ticoid negative feedback system to limit
the production of cortisol during stress
can be impaired by chronic emotional or
physical stress, and by old age27,28. Glu-
cocorticoid-induced hippocampal neuron
damage and deficient transmission of su-
prahypothalamic negative feedback has
been proposed as a major mechanism me-
diating this phenomenon. Indeed, in pa-
tients with depression, the 24-h urinary
free cortisol excretion increases with age,
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TABLE 2
CORRELATION BETWEEN YEARS OF THERAPY AND T SCORE IN PATIENT WITH MDD
Pearson correlations Years of therapy T score
Years of therapy Correlation 1.000 –0.787 (*)
Sig. (2-tailed) 0.000 0.000
N 37 37
T score Correlation –0.787 (**) 1.000
Sig. (2-tailed) 0.000 0.000
N 37 37
* Correlation is significant at the 0.01 level (2-tailed)
TABLE 3
NONPARAMETRIC CORRELATION BETWEEN YEARS OF THERAPY AND T SCORE
IN PATIENT WITH MDD
Spearman’s correlation Years of therapy T score
Years of therapy Correlation 1.000 –0.805
Sig. (2-tailed) 0.000 0.000
N 37 37
T score Correlation –0.805 (*) 1.000
Sig. (2-tailed) 0.000 0.000
N 37 37
* Correlation is significant at the.01 level (2-tailed)
while studies of the HPA axis in aging
population that include persons with
chronic emotional or physical diseases
have shown progressive elevations of eve-
ning plasma cortisol concentrations with
age29.
In MDD hypercortisolism does not
give rise to the usual physical stigmata of
hipercortisolic state (moon face, buffalo
hump, hypertension, easy bruising, pur-
ple striae) and reverts to normal when
the depression remits, either spontane-
ously or due to antidepressants or other
therapy30,31.
Some studies have shown that urinary
cortisol excretion in depression never ex-
ceeds 3-fold upper limit of the normal.
The circadian pattern of plasma cortisol
is less disrupted.
Activation of the pituitary-adrenal
axis is fairly specific of depression among
other conditions of primary affective dis-
orders. So, these findings have eventually
led to the routine use of dexamethasone
suppression test (DST) as a biologic tool
for both the diagnosis and follow-up of
such patients. The research to answer
questions concerning the pathophysiolo-
gy of the hypothalamo-pituitary-adrenal
(HPA) axis dysfunction in patients with
MDD has been focused on MDD. Four hy-
potheses have been proposed to explain
why non-suppression occurs32–34.
These include: 1) increased metabo-
lism of dexamethasone in patients with
MDD35 36, which results in less dexameth-
asone available to suppress the produc-
tion of adrenocorticotropic hormone
(ACTH) in the pituitary; 2) decreased
sensitivity of pituitary glucocorticoid re-
ceptors to dexamethasone, resulting in
less ACTH suppression and cortisol ele-
vation; 3) hyperresponsivity of the adre-
nal gland to ACTH stimulation, resulting
in continued cortisol secretion despite
moderate to significant ACTH suppres-
sion with dexamethasone; and 4) increa-
sed central drive of the pituitary from hy-
pothalamic/limbic structures, which
overrides the action of dexamethasone.
The more so, a combination of the hypoth-
eses should by no means be neglected37,38.
The use of anticortisol drugs has al-
ready produced beneficial conditions in
depression. The mayor role played with
cortisol must have been defective inter-
pretation of cortisol results. If serum
cortisol levels are normal at 8 a.m. and 4
p.m., it has always been considered nor-
mal, without realizing that changes,
sometimes at the immunosuppressive le-
vel, might occur during 24-h circadian
rhythm39,40.
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DEPRESIVNI POREME]AJ KAO MOGU]I ^IMBENIK RIZIKA ZA
RAZVOJ OSTEOPOROZE?
S A @ E T A K
Hipotalamo-hipofizno-adrenalna os slo`eni je kontrolni sustav koji igra zna~ajnu
ulogu prvenstveno u reakciji na stres, pri ~emu glukokortikoidi potiskuju autonomne
(vegetativne), endokrine, imunolo{ke i psihi~ke odgovore na stresni stimulus. Opisali
smo klini~ku, fiziolo{ku i biokemijsku povezanost izme|u osteoporoze i velike depre-
sije. U oba stanja dolazi do hiperaktivnosti HPA osi, LC/NE sustava te povi{enog lu~e-
nja CRH, kortizola i katekolamina. Mnoga stanja i bolesti su povezana uz osteoporozu,
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pa i hiperkorticizam gledamo kao jedno od takvih. Neka novija istra`ivanja povezuju
raniju povijest MDD sa osteoporozom. U velikoj depresiji (engl. Major Depressive Dis-
order, MDD) su zabilje`ene dvije biokemijske abnormalnosti: hiperkorticizam i rezis-
tencija na supresiju deksametazonom. Na{e je istra`ivanje uklju~ivalo 31 bolesnika s
MDD (19 mu{karaca i 12 `ena prosje~ne dobi 37  1,3 godine i raspona od 29–41 go-
dinu) i 17 mu{kih dobrovoljaca (prosje~ne dobi 39  1,6 godina, raspona 34–45 godina).
Svim bolesnicima je odre|ivana razina kortizola u 24-satnom urinu, serumski kortizol
u 8h i 17h, kortizol u testu supresije deksametazonom te denzitometrijski odre|ivana
gusto}a kosti. Radilo se, dakle, o skupini mla|ih mu{karaca i `ena s odr`anim men-
struacijskim ciklusom, u po~etku bez osteoporoze, ali godinama pod antidepresivnom
terapijom. Analiziraju}i ih, na{li smo povi{ene vrijednosti kortizola te pojavu osteo-
poroze, ~iji je razvoj bio posljedica povi{ene razine kortizola. U radu je kori{tena ne-
parametrijska rang-korelacija, kod koje je Spearmanov ro = –0.805, imao statisti~ku
zna~ajnost p < 0.01. Iz svega navedenog se name}e zaklju~ak, da {to se bolesnici dulje
lije~e od depresije razviti }e ja~i oblik hiperkorticizma, {to bi moglo biti uzrokom osteo-
poroze jer je ve} poznato da bolesnici sa nelije~enim Cushingom razvijaju jaki oblik
osteoporoze.
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